Summary:
Do you have moderate to severe atopic dermatitis (for at least one year)?
A clinical trial designed to evaluate if the trial drug, tralokinumab, can affect the body’s immune responses to vaccines for adult patients with moderate-to-severe atopic dermatitis is currently being conducted.
All subjects will receive injections of trial medication or placebo every other week for up to 14 weeks. For all trial participants, the trial will include up to 12 visits to the trial clinic.
Atopic dermatitis (AD) is a chronic inflammatory skin disease. In its severe form, AD is characterized by widespread skin lesions, itch, as well as increased risk of skin infections. AD is associated with a substantial burden that typically includes poor quality of life, sleep disturbance, and reductions in work productivity.
Qualified Participants Must:
• Have had moderate to severe atopic dermatitis for at least 1 year to qualify
Qualified Participants May Receive:
There is no cost to participate in this clinical study and reasonable travel expenses will be reimbursed.